Affimed Company Overview
About Affimed
Affimed NV (NASDAQ:AFMD) is a biopharmaceutical company deeply engaged in the development of immunotherapies to improve treatment outcomes for patients with cancer. Leveraging its proprietary ROCK® (Redirected Optimized Cell Killing) platform, Affimed NV designs and advances a pipeline of innate cell engagers that aim to harness the power of the body's own immune system. The company's lead projects focus on various hematologic and solid tumor indications, reflecting its commitment to bringing novel cancer treatments from concept through clinical trials to commercialization. With operations that span from early-stage research to advanced clinical trials, Affimed NV drives forward with the objective of transforming cancer treatment paradigms to offer hope and life-extending solutions to patients worldwide.
Snapshot
Operations
Produtos e/ou serviços de Affimed
- AFM13, an innate cell engager targeting CD30-positive malignancies.
- AFM24, an EGFR-targeting innate cell engager for solid tumors.
- AFM28, an innovative approach for treating acute myeloid leukemia.
- Partnered with Genentech for discovering new cancer immunotherapies.
- Collaboration with Roivant Sciences to develop and commercialize AFM32, aiming at multiple solid tumor targets.
- Development of AFM26, a B cell maturation antigen (BCMA) targeting therapy for multiple myeloma.
equipe executiva do Affimed
- Dr. Wolfgang Fischer Ph.D.MD, COO, Chief Strategy Officer & Member of Management Board
- Ms. Denise MuellerChief Business Officer & Member of Management Board
- Dr. Andreas Harstrick M.D.Chief Medical Officer & Member of Management Board
- Dr. Shawn M. Leland Pharm.D., R.Ph.Chief Executive Officer
- Prof. Melvyn LittleFounder & Consultant
- Mr. Michael WolfHead of Finance & Administration
- Mr. Alexander FudukidisHead of Investor Relations & Director of Investor Relations
- Mary Beth SandinVice President of Marketing & Communications